The challenges of coronary bifurcation angioplasty are linked to the fractal geometry of their anatomy, responsible for the differences in diameter between the different segments with risk of stent malposition in the main branch and difficulty to access the side branch. Dedicated stents for bifurcation have been developed to reduce these potential risks. The BiOSS ® LIM C stent (Balton, Warsaw, Poland) is a Cobalt Chrome drug eluting stent with Sirolimus dedicated to the treatment of bifurcation lesions.

Our single-center retrospective study included 173 consecutive patients treated for a bifurcation lesion with a BiOSS ® LIM C stent between December 2017 and February 2020. The mean age was 71±11.6 years. The percentage of true bifurcation lesions was 27.2%. The angioplasty success rates for the main branch and the side branch were respectively 100% and 99.4%. The mean duration of follow-up was 311 days. We observed during the follow-up: 4 cardiovascular deaths (2.3%), 5 myocardial infarctions (2.9%), 2 stent thrombosis (1.2%), 10 TLR (6%), 16 TVR (9.2%), 18 TVF (10.4%). The probabilities of overall survival, survival without cardiovascular death or myocardial infarction and survival without TVF are respectively 95%, 90% and 81%.

Angioplasty of coronary bifurcation lesions with a dedicated stent BiOSS ® LIM C is safe and provides very good immediate and long-term results.